Opinion

Video

Clinical Management Considerations: Pneumonitis associated with T-DXd

Author(s):

Hope Rugo, MD,Aditya Bardia, MD, MPH

Experts on breast cancer provide clinical insights on the management of pneumonitis associated with trastuzumab deruxtecan.

Video content above is prompted by the following:

  • How often do you see pneumonitis in your clinical practice with trastuzumab deruxtecan (T-DXd)? Are there any potential patient risk factors for community oncologists to be aware of?
Related Videos
5 experts are featured in this series
5 experts are featured in this series
2 experts are featured in this series.
Related Content
Breast cancer | Image Credit: ©Sebastian Kaulitzki – stock.adobe.com
January 28th 2025

Inavolisib Plus Palbociclib/Fulvestrant Shows OS Benefit in Endocrine-Resistant, PIK3CA-Mutated, HR+, HER2– Breast Cancer

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

David Rimm, MD, PhD, Yale Cancer Center
January 21st 2025

Quantitative IHC Assays May Bridge Gaps in Breast Cancer IHC Test Concordance

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.
January 18th 2025

The OncFive: Top Oncology Articles for the Week of 1/12

FDA
January 17th 2025

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer